Using surveillance data to determine treatment rates and outcomes for patients with chronic hepatitis C virus infection

Hepatology

Volumn 59, Issue 4, 2014, Pages 1343-1350

  Lattimore, Sam ^a   Irving, Will ^b,m   Collins, Sarah ^a   Penman, Celia ^a   Ramsay, Mary ^a   Jalal, Hamid ^c   Matthews, Melanie ^c   Smith, Rachael ^c   Ashley, Chas ^d   Muir, Peter ^d   Atkins, Mark ^e   Green, Mark ^e   Mayoh, Lesley ^e   Croall, John ^f   Vicca, Tony ^g   Locklan, Julia ^h   Waugh, Sheila ^h   Ijaz, Samreen ^a   Ngui, Siew Lin ^a   Tedder, Richard ^a   Vallapil, Manoj ^h   Boxall, Elizabeth ^a   Mowbray, Janet ^a   Lewis, David ⁱ   Hale, Antony ⁱ   Henderson, Ralph ^j   Johnson, David ^j   Zuckerman, Mark ^j   Blackley, Alan ^k   Klapper, Paul ^k   Longbone, Matthew ^l   Ibrahim, Mohammed Osman Hassan ^l   Prichett, Lisa ^m   Silles, Josephine ⁿ   Hesketh, Louise ^o   Ashton, Preston Lynne ^p   Hart, Ian ^p   Oliver, Tony ^q   Couto Parada, Xose ^q   Al Ghusein, Hasan ^r   Rice, Phil ^r   Hewitt, Graham ^s   Underhill, Gillian ^s   Kidd, Mike ^t   Luton, Peter ^t   Baker, Mark ^u   Nash, James ^u   more..

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

^b NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^c ADDENBROOKE S HOSPITAL   (United Kingdom)

^d Bristol HPA Laboratory   (United Kingdom)

^e CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^f Chester Microbiology Laboratory Countess of Chester Hospital ^*  (United Kingdom)

^g DIANA PRINCESS OF WALES HOSPITAL   (United Kingdom)

^h NEWCASTLE GENERAL HOSPITAL   (United Kingdom)

ⁱ LEEDS TEACHING HOSPITALS NHS TRUST   (United Kingdom)

^j KING S COLLEGE HOSPITAL   (United Kingdom)

^k MANCHESTER ROYAL INFIRMARY   (United Kingdom)

^l ROYAL SUSSEX COUNTY HOSPITAL   (United Kingdom)

^m QUEEN S MEDICAL CENTRE   (United Kingdom)

ⁿ NORTH MIDDLESEX UNIVERSITY HOSPITAL   (United Kingdom)

^o ROYAL PRESTON HOSPITAL   (United Kingdom)

^p ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

^q BARTS HEALTH NHS TRUST   (United Kingdom)

^r ST GEORGE S HOSPITAL   (United Kingdom)

^s ST MARY S HOSPITAL   (United Kingdom)

^t UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

^u WILLIAM HARVEY HOSPITAL   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; VIRUS RNA;

ADOLESCENT; ADULT; AGED; ANTIVIRAL THERAPY; ARTICLE; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NONHUMAN; PREDICTIVE VALUE; PRIORITY JOURNAL; SENTINEL SURVEILLANCE; TREATMENT OUTCOME; TREATMENT RESPONSE; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ALGORITHMS; ANTIVIRAL AGENTS; DATABASES, FACTUAL; ENGLAND; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RNA, VIRAL; SENSITIVITY AND SPECIFICITY; SENTINEL SURVEILLANCE; TREATMENT OUTCOME; VIRAL LOAD; YOUNG ADULT;

EID: 84896488012     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.26926     Document Type: Article

References (27)

1. Harris RJ, Ramsay M, Hope VD, Brant L, Hickman M, Foster GR, et al. Hepatitis C prevalence in England remains low and varies by ethnicity: an updated evidence synthesis. Eur J Public Health 2012;22:187-192.
2. Kasahara A, Tanaka H, Okanoue T, Imai Y, Tsubouchi H, Yoshioka K, et al. Interferon treatment improves survival in chronic hepatitis C patients showing biochemical as well as virological responses by preventing liver-related death. J Viral Hepat 2004;11:148-156.
3. Veldt BJ, Heathcote EJ, Wedemeyer H, Reichen J, Hofmann WP, Zeuzem S, et al. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med 2007;147:677-684.
4. Yoshida H, Arakawa Y, Sata M, Nishiguchi S, Yano M, Fujiyama S, et al. Interferon therapy prolonged life expectancy among chronic hepatitis C patients. Gastroenterology 2002;123:483-491.
5. Irving WL, Smith S, Cater R, Pugh S, Neal KR, Coupland CA, et al. Clinical pathways for patients with newly diagnosed hepatitis C-what actually happens. J Viral Hepat 2006;13:264-271.
6. Mohsen AH; Trent HCV Study Group. The epidemiology of hepatitis C in a UK health regional population of 5.12 million. Gut 2001;48:707-713.
7. Zein NN, Rakela J, Krawitt EL, Reddy KR, Tominaga T, Persing DH. Hepatitis C virus genotypes in the United States: epidemiology, pathogenicity, and response to interferon therapy. Collaborative Study Group. Ann Intern Med 1996;125:634-639.
8. Dusheiko G, Schmilovitz-Weiss H, Brown D, McOmish F, Yap PL, Sherlock S, et al. Hepatitis C virus genotypes: an investigation of type-specific differences in geographic origin and disease. Hepatology 1994;19:13-18.
9. McOmish F, Yap PL, Dow BC, Follett EA, Seed C, Keller AJ, et al. Geographical distribution of hepatitis C virus genotypes in blood donors: an international collaborative survey. J Clin Microbiol 1994;32:884-892.
10. Nousbaum JB, Pol S, Nalpas B, Landais P, Berthelot P, Bréchot C. Hepatitis C virus type 1b (II) infection in France and Italy. Collaborative Study Group. Ann Intern Med 1995;122:161-168.
11. Abdulkarim AS, Zein NN, Germer JJ, Kolbert CP, Kabbani L, Krajnik KL, et al. Hepatitis C virus genotypes and hepatitis G virus in hemodialysis patients from Syria: identification of two novel hepatitis C virus subtypes. Am J Trop Med Hyg 1998;59:571-576.
12. Chamberlain RW, Adams N, Saeed AA, Simmonds P, Elliott RM. Complete nucleotide sequence of a type 4 hepatitis C virus variant, the predominant genotype in the Middle East. J Gen Virol 1997;78(Pt 6):1341-1347.
13. Booth JC, O'Grady J, Neuberger J; The Royal College of Physicians of London and the British Society of Gastroenterology. Clinical guidelines on the management of hepatitis C. Gut 2001;49(Suppl. 1):I1-21.
14. Health Protection Agency. Hepatitis C in England: an update 2007. London: Health Protection Agency; 2007.
15. Health Protection Agency. Hepatitis C in the UK 2012. London: Health Protection Agency; 2012.
16. Brant LJ, Hurrelle M, Balogun MA, Klapper P, Ahmad F, Boxall E, et al. Sentinel laboratory surveillance of hepatitis C antibody testing in England: understanding the epidemiology of HCV infection. Epidemiol Infect 2007;135:417-426.
17. Brant LJ, Hurrelle M, Balogun MA, Klapper P, Ramsay ME. Where are people being tested for anti-HCV in England? Results from sentinel laboratory surveillance. J Viral Hepat 2008;15:729-739.
18. Lettmeier B, Mühlberger N, Schwarzer R, Sroczynski G, Wright D, Zeuzem S, et al. Market uptake of new antiviral drugs for the treatment of hepatitis C. J Hepatol 2008;49:528-536.
19. Health Protection Agency. Hepatitis C in the UK 2011. London: Health Protection Agency; 2011.
20. Department of Health. Hepatitis C Action Plan for England. London: Department of Health; 2004.
21. Bini EJ, Bräu N, Currie S, Shen H, Anand BS, Hu KQ, et al. Prospective multicenter study of eligibility for antiviral therapy among 4, 084 U.S. veterans with chronic hepatitis C virus infection. Am J Gastroenterol 2005;100:1772-1779.
22. Kanwal F, Hoang T, Spiegel BMR, Eisen S, Dominitz JA, Gifford A, et al. Predictors of treatment in patients with chronic hepatitis C infection-role of patient versus nonpatient factors. Hepatology 2007;46:1741-1749.
23. Butt AA, Justice AC, Skanderson M, Rigsby MO, Good CB, Kwoh CK. Rate and predictors of treatment prescription for hepatitis C. Gut 2007;56:385-389.
24. Guidelines CP. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 2011;55:245-264.
25. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009;49:1335-1374.
26. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958-965.
27. Department of Health. Healthy Lives, Healthy People: our strategy for public health in England. London: Department of Health; 2010.